Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1571652
PUBLISHER: Grand View Research | PRODUCT CODE: 1571652
Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), By Treatment, By Distribution Channels, By Region, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Schizophrenia Drugs Market Growth & Trends:
The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.3% from 2024 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.
Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.
The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.
Schizophrenia Drugs Market Report Highlights:
- The second-generation-antipsychotics held the largest market revenue share of 73.0% in 2023. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
- The injectable antipsychotics treatment segment held the largest market revenue share in 2023. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
- The hospital pharmacies segment held the largest market revenue share in 2023. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
- North America schizophrenia drugs market held the largest market revenue share of 39.0% in 2023. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.
Product Code: GVR-2-68038-222-8
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Schizophrenia Drugs Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Schizophrenia Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Schizophrenia Drugs Market: Class Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Schizophrenia Drugs Market: Class Movement Analysis, 2023 & 2030 (USD Million)
- 4.2.1. Second-Generation Antipsychotics
- 4.2.1.1. Second-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.2. Risperdal (Risperidone)
- 4.2.1.2.1. Risperdal (Risperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.3. Invega (Paliperidone)
- 4.2.1.3.1. Invega (Paliperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.4. Zyprexa (Olanzapine)
- 4.2.1.4.1. Zyprexa (Olanzapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.5. Geodon (Ziprasidone)
- 4.2.1.5.1. Geodon (Ziprasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.6. Seroquel (Quetiapine)
- 4.2.1.6.1. Seroquel (Quetiapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.7. Latuda (Lurasidone)
- 4.2.1.7.1. Latuda (Lurasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.8. Aristada (Aripiprazole Lauroxil)
- 4.2.1.8.1. Aristada (Aripiprazole Lauroxil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.9. Fanapt (Iloperidone)
- 4.2.1.9.1. Fanapt (Iloperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.10. Saphris (Asenapine)
- 4.2.1.10.1. Saphris (Asenapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1.11. Vraylar (Cariprazine)
- 4.2.1.11.1. Vraylar (Cariprazine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.2. Third-Generation Antipsychotics
- 4.2.2.1. Third-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.2.2. Abilify (Aripiprazole)
- 4.2.2.2.1. Abilify (Aripiprazole) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.2.1. Second-Generation Antipsychotics
- 4.3. Others
- 4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.2. First-Generation Antipsychotics
- 4.3.2.1. First-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.3. Generics
- 4.3.3.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Schizophrenia Drugs Market: Treatment Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Schizophrenia Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
- 5.2.1. Oral Antipsychotics
- 5.2.1.1. Oral Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.2. Injectable Antipsychotics
- 5.2.2.1. Injectable Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.2.1. Oral Antipsychotics
Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Schizophrenia Drugs Market: Distribution channel Movement Analysis, 2023 & 2030 (USD Million)
- 6.2.1. Hospital Pharmacies
- 6.2.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.2. Retail Pharmacies
- 6.2.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.3. Online Pharmacies
- 6.2.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.4. Others
- 6.2.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.2.1. Hospital Pharmacies
Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis
- 7.1. Schizophrenia Drugs Market Share, By Region, 2023 & 2030 (USD Million)
- 7.2. North America
- 7.2.1. North America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. U.K.
- 7.3.2.1. U.K. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Italy Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Spain Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Denmark Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Sweden Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Norway Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
- 7.4.2.1. China Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
- 7.4.3.1. Japan Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. South Korea Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Australia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Thailand Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Argentina Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
- 7.6.2.1. Saudi Arabia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
- 7.6.3.1. UAE Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
- 7.6.4.1. South Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. Johnson & Johnson
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Bristol-Myers Squibb/ Otsuka Pharma
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. AstraZeneca
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Sumitomo Dainippon
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Eli Lilly & Company
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Alkermes
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Vanda Pharma
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Allergan
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Pfizer
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. H. Lundbeck A/S
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.1. Johnson & Johnson
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.